Phaseline

Companies › Stella Pharma

Stella Pharma: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SPM-011
Boron compound for boron neutron capture therapy (BNCT)
–Phase 2Unresectable Angiosarcoma–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05601232SPM-011Phase 2Unresectable AngiosarcomaOncologyNov 2024

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

CNBG-Virogin Biotech (Shanghai) Dendreon Hangzhou Converd Abscint NV/SA Beijing Gene Key Life Technology

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.